TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01917695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy
Description: 50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: 50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
Study: NCT01952847

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
Study: NCT02484586

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Prototype lens material

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Prototype lens material
Study: NCT01917695

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Hysterectomy
Description: Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Hysterectomy
Description: Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
Study: NCT02032771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 IPL and ResurFX
Description: The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
Study: NCT04624802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maternal exercise
Description: The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
Study: NCT03363893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Study: NCT02484586

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Control lens for presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A
Description: Control lens for presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A
Description: Control lens for presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A
Description: Control lens for non-presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Control lens for non-presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A
Description: Control lens for presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: 58% Poly-HEMA
Description: Control lens for presbyope group

Intervention type: DEVICE
Group type: OTHER
Intervention: Omafilcon A
Description: Control lens for non-presbyope group
Study: NCT01375673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking Strength Training Bicycling
Study: NCT04434248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Study: NCT02870972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Plasma kallikrein inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Plasma kallikrein inhibitor
Study: NCT03363893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
Study: NCT02026596

Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging

Intervention type: PROCEDURE
Intervention: Cerebral microdialysis catheter insertion
Description: Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
Study: NCT03571178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
Study: NCT03877588

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Support
Description: Preoperative oral nutritional support is provided according to malnutrition grade
Study: NCT02099383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
Study: NCT02870972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Plasma kallikrein inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Plasma kallikrein inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01513330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio
Description: Ostomy product - 1 piece closed bag

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio
Description: Ostomy product - 1 piece closed bag

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
Study: NCT01515696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrografin
Description: Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
Study: NCT02253576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaled 7% hypertonic saline
Description: Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nebulized normal saline
Description: Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
Study: NCT01513330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
Study: NCT02092532

Intervention type: DRUG
Group type: OTHER
Intervention: Rescue Intravitreal Aflibercept Injection
Description: Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rescue Therapy with PDT, Laser or Intravitreal Steroids
Description: Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
Study: NCT02523547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir
Description: 0.5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude
Description: 0.5mg/day
Study: NCT01403870

Intervention type: OTHER
Intervention: Physical Therapy
Description: The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
Study: NCT03124693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow DCI pulse oximeter sensor
Study: NCT00073398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: Hyperacute Lung Cancer Cell Vaccine
Description: At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
Study: NCT03144544

Intervention type: PROCEDURE
Intervention: Pediatric surgical procedures
Description: Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.

Intervention type: PROCEDURE
Intervention: Pediatric surgical procedures
Description: Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
Study: NCT00915083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
Study: NCT00360477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal
Description: Bioglue that seals the kidney

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cope Loop
Description: Nephrostomy tube for fluid drainage from the kidney

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Stitch
Description: Stitch that closes the kidney
Study: NCT01179776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin
Description: Ilomedin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin and standard low dose treatment
Study: NCT01578213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: * Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use
Study: NCT01921647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Study: NCT03043430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 100 MG/ML
Description: Administer ketamine via mucosal atomization device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 5 MG/ML
Description: Administer midazolam via mucosal atomization device
Study: NCT04361812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS632
Description: Subcutaneous injection of HS632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Xolair®)
Description: Subcutaneous injection of Omalizumab Xolair®)
Study: NCT02339597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP) initiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP) initiation
Study: NCT01535001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 20mg x 1/day for three weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.
Study: NCT01907932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VScan Ultrasound (GE Healthcare, USA)
Description: VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
Study: NCT05021445

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: plates based exercises
Description: 12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: 12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
Study: NCT01013961

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alemtuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT04548986

Intervention type: DEVICE
Group type: OTHER
Intervention: Aktiia.product
Description: The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
Study: NCT00778232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin tablets 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin tablets 800 mg
Study: NCT02634047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional technique
Description: transesophageal echocardiography probe was inserted using a traditional blind insertion technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope technique
Description: transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
Study: NCT03785106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Description: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Description: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Study: NCT00882115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract (BSE)
Description: BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
Study: NCT00981708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone and Cyclophosphamide
Description: Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)
Study: NCT04250779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CapMedic smart inhaler device
Description: The CapMedic device provides active coaching to promote correct and regular use of MDI.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video-based guidance
Description: Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
Study: NCT04789343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
Study: NCT00425607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
Study: NCT02901769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making
Study: NCT03673995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol+L-tyrosine
Description: PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
Study: NCT01202799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% w/w diclofenac sodium topical gel
Description: 2% w/w diclofenac sodium topical gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% w/w diclofenac sodium topical solution
Description: 1.5% w/w diclofenac sodium topical solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75 mg diclofenac sodium delayed release tablet
Description: 75 mg diclofenac sodium delayed release tablet